Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement-Mediated Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for C1S drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Active) | C1S Wild-Type Serine Protease (Full-length / Catalytic Domain). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed for authentic glycosylation. | View C1S Products |
| Antigen (Mutant) | C1S S632A Catalytic Dead Mutant. Active site mutant for negative control and crystallography. Sequence Verified. | View C1S Products |
| Gene Delivery | C1S Promise-ORF / Lentivirus. Full-length ORF for stable cell line generation in pathway reconstitution assays. | View C1S Products |
| Benchmark Ab | Anti-C1S (Sequence of Sutimlimab). Recombinant positive control for neutralization and binding assays. | View C1S Products |
| Validator | C1S siRNA Set. For knockdown verification and specificity controls in cell-based assays. | View C1S Products |
| Related Target: C1R | C1R Serine Protease. Essential for selectivity counter-screening (high homology to C1S). | View C1R Products |
| Related Target: C3 | C3. Central convergence node of all complement pathways; combination and bypass strategy target. | View C3 Products |
| Related Target: C4 | C4 Complement Protein. Natural substrate for C1S enzymatic activity assays. | View C4 Products |
| Related Target: C1Q | C1Q Complex. Upstream recognition component for classical pathway reconstitution. | View C1Q Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Cyno, and Mouse C1S ortholog proteins available with >95% purity; sequence verified for PK/PD and tox study validation. |
| Subfamily counter-screening (C1R homology) | C1R homolog protein strictly verified by mass spec for anti-C1S specificity and selectivity. |
| Proteolytic activity & inhibition quantification | Catalytically competent wild-type and active-site mutant C1S proteins for mechanistic and enzymatic studies. |
| Lack of clinical positive controls | Benchmark Anti-C1S antibody (Sutimlimab sequence) as recombinant reference standard. |
| Off-target protease liability | Broad protease selectivity panel (C1R, Thrombin, MASPs) with high-purity homologs for off-target screening. |
| False positives in cellular assays | Validated C1S siRNA included for target-specificity verification in functional models. |
| Catalytic dead control for assay validation | S632A Mutant Protein available as negative control for enzymatic assays and crystallography. |
| High-concentration stability for SC formulation | Aggregate-free C1S protein for viscosity and self-interaction studies. |
Live C1S R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for C1S therapeutics is intensifying, with major players shifting focus from broad immunosuppression to precision classical complement inhibition. As first-generation anti-C1S antibody therapies gain regulatory approval in cold agglutinin disease, the next wave of R&D is targeting broader autoimmune indications, subcutaneous formulations, and oral small-molecule protease inhibitors. Pipeline evolution includes next-generation monoclonal antibodies optimized for subcutaneous delivery (e.g., Sanofi's Riliprubart) and emerging modalities such as RNA/antisense therapies. The growing understanding of C1S structure and mutations (e.g., rs12146727, EDSPD2 variants) further enables personalized approaches and selective inhibitor design.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-C1S mAb (IV) | Sanofi (Enjaymo / Sutimlimab) | Cold Agglutinin Disease, Autoimmune Hemolytic Anemia | Classical Pathway Hemolysis Assay (Need catalytically active C1S + C4/C2 substrates) |
| Anti-C1S mAb (Sub-Q) | Sanofi (Riliprubart), Next-gen Developers | Chronic Autoimmune Disorders (e.g., wAIHA, MG) | High-Concentration Stability & Viability Assay (Need monomeric C1S antigen for epitope mapping) |
| Small Molecule Inhibitor | Emerging Biotech / Pharma | Transplant Rejection, Rheumatoid Arthritis, Nephropathy | Catalytic Inhibition & Selectivity Assay (Need WT & active-site mutant C1S proteins) |
| RNAi / Antisense | Early-stage players | Chronic Complement Dysregulation | Target Knockdown Validation (Need accurate siRNA and ORF controls) |
Key Molecular Features of C1S (Target Information)
- Functional Domains: CUB 1, EGF-like (calcium-binding), CUB 2 (UniProt P09871).
- Key Mutations: rs12146727 (dbSNP), rs886040975 (EDSPD2), and a variant of uncertain significance (EDSPD2). These mutations may affect epitope conformation or small-molecule binding pockets, underscoring the need for mutant protein libraries in drug screening.
- Target Identity: Verified as UniProt P09871 primary entry, identical to requested target C1S.
Related Targets for Cross-Selling
Build a complete classical pathway drug screening solution by combining C1S reagents with:
- C1R (View C1R Products) – for selectivity counter-screening.
- C4 (View C4 Products) – downstream substrate for functional cleavage assays.
- C1Q (View C1Q Products) – for C1 complex reconstitution.
- C3 (View C3 Products) – for combination and bypass studies.